Carvykti® Is the First and Only Cell Therapy to Significantly Extend Overall Survival Versus Standard Therapies for Patients With Multiple Myeloma as Early as Second Line
Carvykti®是第一個也是唯一一個細胞療法,能顯著延長多發性骨髓瘤患者的整體生存期,甚至早期作爲第二線療法
Carvykti® Is the First and Only Cell Therapy to Significantly Extend Overall Survival Versus Standard Therapies for Patients With Multiple Myeloma as Early as Second Line
Carvykti®是第一個也是唯一一個細胞療法,能顯著延長多發性骨髓瘤患者的整體生存期,甚至早期作爲第二線療法
譯文內容由第三人軟體翻譯。